Cancer cell:新型核酸药物可以治疗扩散性乳腺癌

2015-03-12 佚名 生物谷

NfkB是一类十分重要的转录因子,它参与调节了细胞的炎症反应,免疫应答,细胞增殖、分化以及存活等许多方面。同时,研究也发现在许多种的癌症微环境中NF-kB的非正常表达能够引起炎症反应,从而促进癌症的扩散与侵染,这说明NF-kB是联系炎症反应与癌症的关键分子。目前有许多NF-kB的负向调节因子都被认为可能具有抑制肿瘤恶化的潜力。 长非编码RNA(lncRNA)是一类包含大量成员的RNA家族。这一类

NfkB是一类十分重要的转录因子,它参与调节了细胞的炎症反应,免疫应答,细胞增殖、分化以及存活等许多方面。同时,研究也发现在许多种的癌症微环境中NF-kB的非正常表达能够引起炎症反应,从而促进癌症的扩散与侵染,这说明NF-kB是联系炎症反应与癌症的关键分子。目前有许多NF-kB的负向调节因子都被认为可能具有抑制肿瘤恶化的潜力。

长非编码RNA(lncRNA)是一类包含大量成员的RNA家族。这一类RNA长度超过200bp,不具有翻译成蛋白质的能力,因此得名。虽然不具有传统RNA的功能,但lncRNA被发现具有许多调节转录因子活性的能力。而且许多研究证明有些lncRNA在肿瘤增殖,凋亡,扩散以及稳态维持方面具有重要的功能。最近,中山大学中山纪念医院乳腺癌研究中心的song erwei在Cell子刊《cancer cell》上发表了关于lncRNA调节NF-kB活性进而控制乳腺癌扩散的分子机制。
 
首先,作者利用乳腺癌细胞系MDA-MB-231作为研究对象分析了在TNF-a或IL-1b刺激下转录组的变化。结果显示,在炎性因子刺激下,有23种lncRNA发生了上调,28种发生了下调。其中包括一种叫做NKILA的lncRNA。通过PCR的方式,作者鉴定出了NKILA是一个长度为2570nt的转录本。作者利用免疫原位杂交的手段发现NKILA主要定位于胞质中。之后,作者通过加入NF-kB入核的抑制剂Sc-3060或JSH-23来阻断NF-kB的活性,结果显示NF-kB的失活抑制了NKILA的上调。作者通过结合突变与染色质免疫共沉淀的手段证明了NF-kB可以作用于NKILA编码区上游的顺式调控区域。这一结果说明炎性刺激引起的NKILA上调依赖于NF-kB的活性。
 
之后,作者通过实验发现NKILA的表达量在低扩散性的细胞系中药远高于在高扩散性的细胞系中。由于NF-kB能够正向促进肿瘤的扩散,作者希望了解NKILA是否与NF-kB的活性存在反馈抑制的作用。作者通过人为抑制乳腺癌细胞中NKILA的表达水平,发现能够提高NF-kB的表达量以及入核的效率。以上实验说明NKILA是NF-KB的负向调节因子。
 
进一步,作者通过体外的生化试验与荧光成像实验证明NKILA能够抑制Ikb在静息状态与激活状态下磷酸化与降解。而这一功能依赖于它与p65-p50-IkB的相互作用。之后,作者通过一系列突变与生化实验找到了NKILA与IKB复合体相互作用的关键位点:两个RNA发卡结构。其中一个与NK-kB的DNA结合位点十分相近。
 
最后,作者通过体外与体内的功能学检测分别证明了NKILA对于促进肿瘤细胞发生凋亡以及抑制肿瘤扩散的能力,并能够显著延长患癌小鼠的存活时间。
 
原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869041, encodeId=c5a718690411b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Jun 30 19:39:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780647, encodeId=3f591e80647fb, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jan 21 10:39:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959292, encodeId=642b195929293, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 26 03:39:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18171, encodeId=9dd1181e164, content=临床太难, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 19:23:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-06-30 heli0118
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869041, encodeId=c5a718690411b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Jun 30 19:39:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780647, encodeId=3f591e80647fb, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jan 21 10:39:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959292, encodeId=642b195929293, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 26 03:39:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18171, encodeId=9dd1181e164, content=临床太难, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 19:23:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869041, encodeId=c5a718690411b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Jun 30 19:39:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780647, encodeId=3f591e80647fb, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jan 21 10:39:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959292, encodeId=642b195929293, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 26 03:39:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18171, encodeId=9dd1181e164, content=临床太难, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 19:23:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-05-26 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869041, encodeId=c5a718690411b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Jun 30 19:39:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780647, encodeId=3f591e80647fb, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jan 21 10:39:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959292, encodeId=642b195929293, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 26 03:39:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18171, encodeId=9dd1181e164, content=临床太难, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.226.177.**, createdTime=Thu Mar 12 19:23:00 CST 2015, time=2015-03-12, status=1, ipAttribution=)]
    2015-03-12 116.226.177.**

    临床太难

    0